Constanze Schneider
Overview
Explore the profile of Constanze Schneider including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
333
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider C, Spaink H, Alexe G, Dharia N, Meyer A, Merickel L, et al.
Cancer Res
. 2024 Jul;
84(20):3354-3370.
PMID: 39024560
Tissue-specific differences in the expression of paralog genes, which are not essential in most cell types due to the buffering effect of the partner pair, can make for highly selective...
2.
Mantke R, Schneider C, von Ruesten A, Hauptmann M
Int J Surg
. 2024 Jun;
110(10):6493-6500.
PMID: 38935125
Objective: To compare the survival of palliative stage IV colorectal cancer patients selected for primary tumor resection and systemic treatment (PTR+SYST) to patients with systemic treatment only (SYST). Background: About...
3.
Loew A, Schneider C, Pfluger M, Mantke R, Weylandt K, Gretschel S
Chirurgie (Heidelb)
. 2024 Jun;
95(10):825-832.
PMID: 38861172
Background: Clinical cancer registries are intended to reflect the reality of care through differentiated data analysis and, if necessary, to offer approaches for improving care. Methods: For the years 2000-2018,...
4.
Papathemelis T, Ortmann O, Kohl C, Neuser P, Tol K, Klinkhammer-Schalke M, et al.
J Cancer Res Clin Oncol
. 2024 May;
150(5):279.
PMID: 38802682
Purpose: Endometrial cancer (EC) is one of the most common malignancies among women in western countries. This study aimed to assess data on patient treatment in Germany throughout two decades...
5.
Lin S, Schneider C, Su A, Alexe G, Root D, Stegmaier K
Leukemia
. 2024 Feb;
38(3):652-656.
PMID: 38366087
No abstract available.
6.
Carre J, Herzog B, Reil D, Schneider C, Pfluger M, Lobel M, et al.
HNO
. 2023 Dec;
72(2):90-101.
PMID: 38117331
Background: The impact of the COVID-19 pandemic on potential limitations to the diagnosis and treatment of patients with head and neck tumours has not yet been adequately investigated. There are...
7.
Armbrust R, Ledwon P, Von Rusten A, Schneider C, Sehouli J
Cancers (Basel)
. 2022 Oct;
14(19).
PMID: 36230561
Background: The current therapy of ovarian cancer is based on the so-called “Three-Pillar-Model”, consisting of surgery, chemotherapy and maintenance therapy. This study represents the first major analysis of a federal...
8.
Jayavelu A, Wolf S, Buettner F, Alexe G, Haupl B, Comoglio F, et al.
Cancer Cell
. 2022 Mar;
40(3):301-317.e12.
PMID: 35245447
Acute myeloid leukemia (AML) is an aggressive blood cancer with a poor prognosis. We report a comprehensive proteogenomic analysis of bone marrow biopsies from 252 uniformly treated AML patients to...
9.
Rothenburger T, Thomas D, Schreiber Y, Wratil P, Pflantz T, Knecht K, et al.
J Exp Clin Cancer Res
. 2021 Oct;
40(1):317.
PMID: 34641952
Background: SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1...
10.
Wilke A, Doebele C, Zindel A, Lee K, Rieke S, Ceribelli M, et al.
Blood
. 2021 Oct;
139(4):538-553.
PMID: 34624079
Burkitt lymphoma (BL) is an aggressive lymphoma type that is currently treated by intensive chemoimmunotherapy. Despite the favorable clinical outcome for most patients with BL, chemotherapy-related toxicity and disease relapse...